Removing Transfusion Dependence as a Barrier to Hospice Enrollment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Proportion of Eligible Patients Choosing to Participate in the Care Model Under Study Rather Than Standard of Care.
研究概览
简要总结
Hospice care at the end of life (EOL) includes a multidisciplinary team that helps patients and families focus on symptom control and quality of life. For patients with "solid" (e.g. lung, breast) cancers it has been shown to improve quality of life for both patients and families. Unfortunately, patients with blood cancers (e.g. leukemia, lymphoma) often delay their enrollment and receive more aggressive care at the EOL. One factor in this delay is the inability for patients to receive blood transfusions while on hospice. Patients with blood cancers often require frequent blood transfusions near the EOL for symptom control. The structure of Medicare hospice benefit makes coverage for transfusions financially unfeasible for hospice agencies, and therefore patients with blood cancers will delay enrollment onto hospice in order to continue to receive blood transfusions.
The objective of this study is to evaluate whether removing this financial burden, through external funding of blood transfusions for patients while on hospice, will encourage patients with blood cancers to enroll on hospice earlier and ultimately improve their and their caregivers EOL care.
详细描述
The overall objective is to demonstrate the feasibility of providing blood transfusions to patients with HM enrolled on hospice, and to evaluate both EOL care quality outcomes in these patients, and caregiver quality of life and perception of patient EOL care quality. Palliative blood transfusions will be provided to patients on this study free of cost through study funding. The hypothesis is that removing transfusion dependence as a barrier to hospice enrollment for patients with hematologic malignancies will result in improved EOL care quality outcomes. This hypothesis is derived from our previous research demonstrating that for Medicare beneficiaries with HM, transfusion dependence poses a significant barrier to timely hospice referral.
The study design is to conduct a single-center, prospective pilot study . Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be pursued for enrollment. These patients will be offered to enroll in this study in which funding will be provided to receive palliative blood transfusions while enrolled on hospice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 and older
- •Advanced hematologic malignancies
- •Hospice eligible as determined by their primary hematologist
- •Have opted to forego further cancer-directed therapy.
- •Transfusion Dependent: Requiring at least 2 units of blood products
排除标准
- •Patients with major psychiatric illness
- •Patients without the ability to speak and read English
研究组 & 干预措施
Intervention arm
Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment.
干预措施: Transfusion support (Other)
结局指标
主要结局
Proportion of Eligible Patients Choosing to Participate in the Care Model Under Study Rather Than Standard of Care.
时间窗: Through study completion, on average 2 years
Measured as: the number of eligible patients approached and number who elect to enter the study and participate in the novel care model rather than through the traditional hospice care model.
次要结局
- Time Enrolled on Hospice.(From enrollment until death or withdrawal of consent, on average 2 months.)
- Number of Days in the ICU in the Last 30 Days of Life(Last 30 days of life.)
- Death in an Acute Care Hospital(From enrollment until death or withdrawal of consent, on average 2 months.)
- Receipt of Chemotherapy in the Last 14 Days of Life(Last 14 days of life)
研究者
Adam Olszewski
Associate Professor of Medicine
Brown University